Literature DB >> 30234405

Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study.

Vincent Camus1, Sydney Dubois1, Fabrice Jardin1, Hervé Tilly1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30234405     DOI： 10.1080/10428194.2018.1508671

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.

Authors:  Stefan Alig; Charles W Macaulay; David M Kurtz; Ulrich Dührsen; Andreas Hüttmann; Christine Schmitz; Michael C Jin; Brian J Sworder; Andrea Garofalo; Mohammad Shahrokh Esfahani; Barzin Y Nabet; Joanne Soo; Florian Scherer; Alexander F M Craig; Olivier Casasnovas; Jason R Westin; Gianluca Gaidano; Davide Rossi; Mark Roschewski; Wyndham H Wilson; Michel Meignan; Maximilian Diehn; Ash A Alizadeh
Journal:  J Clin Oncol       Date:  2021-04-28       Impact factor: 50.717

2.  Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma.

Authors:  Masahiro Yoshida; Yosuke Nakaya; Katsujun Shimizu; Naoko Tatsumi; Minako Tsutsumi; Hoyuri Fuseya; Mirei Horiuchi; Takuro Yoshimura; Yoshiki Hayashi; Takafumi Nakao; Takeshi Inoue; Takahisa Yamane
Journal:  Sci Rep       Date:  2021-02-02       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.